Update on Weight Loss Medication

Posted by: Macaulay - Posted on:

GPs are experiencing increased demand for weight loss medication. 

Hillview Surgery is currently not able to provide injections for weight loss.

Later this year Tirzepatide (Mounjaro) may become available for a small number of eligible patients (see criteria below). We are still awaiting local guidance in relation to this and will update our website when we get more information.

Potential Eligibility for Tirzepatide (Mounjaro) later in 2025:

BMI ≥40 (or ≥ 37.5 for high risk groups)

AND

4 of these conditions:

  • Type 2 Diabetes
  • Hypertension
  • Cardiovascular Disease (Ischaemic Heart Disease, Stroke, Heart Failure, Peripheral Vascular Disease)
  • Obstructive Sleep Apnoea

Ethnicity Based BMI Adjustment:

High risk groups: Asian, Chinese, Middle Eastern, Black-African, African-Carribean descent.